可溶性尿激酶型纤溶酶原激活物受体与局灶节段性肾小球硬化：基础研究与临床应用之间的差距 - Suppr

Suppr

超能文献

suPAR and FSGS: the gap between bench and bedside.

作者信息

Naesens Maarten, Meijers Björn, Sprangers Ben

出版信息

Transplantation. 2013 Aug 27;96(4):368-9. doi: 10.1097/TP.0b013e31829e6d40.

DOI:10.1097/TP.0b013e31829e6d40

PMID:23851934

Abstract

摘要

相似文献

suPAR and FSGS: the gap between bench and bedside.可溶性尿激酶型纤溶酶原激活物受体与局灶节段性肾小球硬化：基础研究与临床应用之间的差距

Transplantation. 2013 Aug 27;96(4):368-9. doi: 10.1097/TP.0b013e31829e6d40.

Transplantation: Urine--but not serum--suPAR might predict FSGS recurrence.移植：尿中的可溶性尿激酶型纤溶酶原激活物受体（suPAR）而非血清中的suPAR可能预测局灶节段性肾小球硬化（FSGS）复发。

Nat Rev Nephrol. 2013 Aug;9(8):432. doi: 10.1038/nrneph.2013.117. Epub 2013 Jun 25.

Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.尿而非血清可溶性尿激酶受体（suPAR）可识别肾移植候选者复发性 FSGS 病例。

Transplantation. 2013 Aug 27;96(4):394-9. doi: 10.1097/TP.0b013e3182977ab1.

Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.原发性局灶节段性肾小球硬化症患者的尿可溶性尿激酶受体水平升高且具有致病性。

BMC Med. 2014 May 20;12:81. doi: 10.1186/1741-7015-12-81.

Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.鉴定原发性局灶节段性肾小球硬化的潜在生物标志物及其与移植后复发的关系。

Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21.

Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb.使用CytoSorb去除局灶节段性肾小球硬化（FSGS）因子可溶性尿激酶型纤溶酶原激活物受体（suPAR）。

J Clin Apher. 2017 Dec;32(6):444-452. doi: 10.1002/jca.21538. Epub 2017 Mar 29.

Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.采用强化血浆置换及可溶性尿激酶型纤溶酶原激活物受体介导的足细胞β3整合素激活同步监测治疗复发性原发性局灶节段性肾小球硬化症

Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.

Soluble urokinase receptor and focal segmental glomerulosclerosis.可溶性尿激酶型纤溶酶原激活物受体与局灶节段性肾小球硬化

Curr Opin Nephrol Hypertens. 2012 Jul;21(4):428-32. doi: 10.1097/MNH.0b013e328354a681.

Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.尿激酶型纤溶酶原激活剂及其受体在临床和小鼠模型中局灶节段性肾小球硬化进展中的意义。

J Biomed Sci. 2016 Feb 4;23:24. doi: 10.1186/s12929-016-0242-7.

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。

Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.

引用本文的文献

Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.循环中可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平受原发性和继发性肾小球肾炎中肾小球滤过率及蛋白尿的影响。

J Nephrol. 2015 Jun;28(3):299-305. doi: 10.1007/s40620-014-0137-1. Epub 2014 Sep 4.

Permeability factors in focal and segmental glomerulosclerosis.局灶节段性肾小球硬化症中的通透性因素

Adv Chronic Kidney Dis. 2014 Sep;21(5):417-21. doi: 10.1053/j.ackd.2014.05.010.

Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children.血清可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平有助于区分儿童类固醇抵抗型与类固醇敏感型肾病综合征。

Pediatr Nephrol. 2015 Feb;30(2):301-7. doi: 10.1007/s00467-014-2892-6. Epub 2014 Jul 18.

Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor.原发性局灶节段性肾小球硬化与可溶性因子尿激酶型纤溶酶原激活物受体

World J Nephrol. 2013 Nov 6;2(4):103-10. doi: 10.5527/wjn.v2.i4.103.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验